Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies.
暂无分享,去创建一个
[1] C. Hawkins,et al. Fungal infections in the immunocompromised host. , 1984, Clinics in haematology.
[2] J. V. van Cutsem,et al. Itraconazole, a new triazole that is orally active in aspergillosis , 1984, Antimicrobial Agents and Chemotherapy.
[3] J. Gold. Opportunistic fungal infections in patients with neoplastic disease. , 1984, The American journal of medicine.
[4] B. Strom,et al. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. , 1984, Annals of internal medicine.
[5] S. Schrier,et al. Multivariate analysis of factors associated with invasive fungal disease during remission induction therapy for acute myelogenous leukemia , 1984, Cancer.
[6] J. V. van Cutsem. The antifungal activity of ketoconazole. , 1983, The American journal of medicine.
[7] R. Stein,et al. Clinical value of empirical amphotericin B in patients with acute myelogenous leukemia , 1982, Cancer.
[8] W. Lee,et al. Fungal infections in patients with acute leukemia. , 1982, The American journal of medicine.
[9] L. Young. The outlook for antifungal prophylaxis in the compromised host. , 1982, The Journal of antimicrobial chemotherapy.
[10] H. Prentice,et al. KETOCONAZOLE VERSUS NYSTATIN PLUS AMPHOTERICIN B FOR FUNGAL PROPHYLAXIS IN SEVERELY IMMUNOCOMPROMISED PATIENTS , 1982, The Lancet.
[11] E. Ezdinli,et al. Oral amphotericin for candidiasis in patients with hematologic neoplasms. An autopsy study. , 1979, JAMA.
[12] Krick Ja,et al. Opportunistic invasive fungal infections in patients with leukaemia lymphoma. , 1976, Clinics in haematology.
[13] G. W. Snedecor. STATISTICAL METHODS , 1967 .